Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

Fotios Loupakis1,2*, Chiara Cremolini2,9, Dongyun Yang1, Lisa Salvatore2, Wu Zhang1, Takeru Wakatsuki1, Pierre Bohanes1, Marta Schirripa2, Leonor Benhaim1, Sara Lonardi3, Carlotta Antoniotti3, Giuseppe Aprile4, Francesco Graziano5, Annamaria Razzo6, Sara Lucchesi7, Monica Ronzoni8, Ferdinando De Vita9, Giuseppe Tonini10, Alfredo Falcone2, Heinz-Josef Lenz1

1 University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America, 2 Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscana Tumori, Pisa, Italy, 3 Unit of Medical Oncology, Oncology Institute of Veneto, Padua, Italy, 4 Azienda Ospedaliero-Universitaria di Udine, Udine, Italy, 5 Unit of Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy, 6 Section of Biochemistry and Molecular Biology “G. Fornaini”, Department of Biomolecular Sciences, University of Urbino, Urbino, Italy, 7 Unit of Medical Oncology, Azienda USL5 Pontedera, Istituto Toscana Tumori, Pisa, Italy, 8 Unit of Oncology, Istituto Scientifico San Raffaele, Milan, Italy, 9 Unit of Medical Oncology, Seconda Università di Napoli, Naples, Italy, 10 Unit of Medical Oncology, University Campus Biomedico, Rome, Italy

Abstract

Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been investigated in retrospective experiences with contrasting results. We previously reported the association of VEGFA rs833061 C/T variants with PFS in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. The primary objective of this work was to prospectively validate that retrospective finding. A confirmatory analysis of other SNPs of VEGF/VEGFR pathway genes was included.

Experimental design: To detect a HR for PFS of 1.7 for VEGF rs833061 T/T compared to C- variants in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab, setting two-sided α = 0.05 and β = 0.20, 199 events were required. VEGFA rs699946 A/G, rs699947 A/C, VEGFR1 rs9582036 A/C and rs7993418 A/G, VEGFR2 rs11133360 C/T, rs12505758 C/T and rs2305948 C/T and EPAS1 rs4145836 A/G were also tested. Germ-line DNA was extracted from peripheral blood. SNPs were analyzed by PCR and sequencing.

Results: Four-hundred-twenty-four pts were included. At the univariate analysis, no differences according to VEGFA rs833061 C/T variants were observed in PFS (p = 0.38) or OS (p = 0.95). Among analyzed SNPs, only VEGFR2 rs12505758 C- variants, compared to T/T, were associated to shorter PFS (HR: 1.36 [1.05–1.75], p = 0.015, dominant genetic model) and OS, with a trend toward significance (HR: 1.34 [0.95–1.88], p = 0.088). In the multivariate model, this association retained significance (HR: 1.405 [1.082–1.825], p = 0.012) in PFS, that was lost by applying multiple testing correction (p = 0.14).

Conclusion: This prospective experience failed to validate the hypothesized predictive impact of VEGFA rs833061 variants. Retrospective findings on different candidate SNPs were not confirmed. Only VEGFR2 rs12505758 variants, whose prognostic and not predictive impact was previously reported, correlated with PFS. Given the complexity of angiogenesis, it is rather unlikely that a single germ-line SNP might be a good predictor of benefit from bevacizumab.

Citation: Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, et al. (2013) Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE 8(7): e66774. doi:10.1371/journal.pone.0066774

Editor: Xiao-Ping Miao, MOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China

Received March 30, 2013; Accepted May 10, 2013; Published July 4, 2013

Copyright: © 2013 Loupakis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors declared that no competing interests exist.

* E-mail: fotiosloupakis@gmail.com

9 These authors contributed equally to this work.

Introduction

The inhibition of angiogenesis, through the blockade of VEGF/VEGFR pathway, is an effective strategy in the treatment of metastatic colorectal cancer (mCRC). Not only the anti-VEGFA monoclonal antibody bevacizumab (BV) [1,2] but also, in the very last months, the VEGF and PlGF trap afibercept [3] and the multikinase inhibitor regorafenib [4] have demonstrated significant advantages in terms of survival.

By a clinical perspective, the relatively small absolute benefit provided by these new agents, as well as the availability of an increasing number of therapeutic options make the identification of predictive biomarkers an essential need in order to optimize the
Predictors of Benefit from Bevacizumab

use of antiangiogenic agents. Unfortunately, up today, this need is still unsolved.

With regard to BV, despite several attempts spanning from the pharmacodynamic to the imaging approach [5-6], no biomarkers of benefit or resistance have been identified so far. Looking at the biology of angiogenesis, increasing evidences highlight the contribution of tumour microenvironment to cancer progression. The so called “niche” [7-8], including endothelial and mesenchimal cells, plays a central role in the growth of new vessels, that is therefore a largely host-mediated, besides tumor-mediated, phenomenon. Based on these considerations, the pharmacogenetic approach, evaluating the impact of germ-line variability on drugs’ efficacy, earned success as a promising tool to disclose potential predictors of benefit. Nevertheless, up today, several retrospective experiences have provided inconclusive and even contrasting results [9-14].

Our group retrospectively investigated the association of 4 VEGFA SNPs with survival parameters in a cohort of 111 mCRC patients treated with upfront FOLFIRI plus BV and in a historical, non-randomized, cohort of 107 mCRC patients treated with upfront FOLFIRI alone [10]. A significant association of VEGFA rs833061 C/T allelic variants with PFS and OS was reported in the BV-group, but not in the control group. When treated with BV, patients bearing VEGFA rs833061 T/T genotype had significantly shorter PFS compared to those carrying at least one C- allele, both in the univariate and in the multivariate model. Moreover, the significance of an exploratory interaction test, though affected by the non-randomization bias, suggested that this association could be actually related to the effect of BV.

Our goal was to validate prospectively the association of this SNP with outcome in a clinical trial designed and powered to confirm the SNP as a predictive biomarker in a population of previously untreated mCRC receiving first-line FOLFIRI plus BV, just like the population included in the retrospective cohort.

In the meanwhile, new appealing results were provided by the largest pharmacogenetic analysis related to BV and the outcome of patients with different solid malignancies, randomized to receive or not the antiangiogenic drug in first-line randomized phase III trials [15]. Among 158 investigated SNPs in potentially relevant genes, Lambrechts et al. identified some promising SNPs in VEGFA, VEGFR1/2 and EPAS1. We therefore included as secondary endpoints of our prospective trial the evaluation of all those SNPs that showed a possible correlation with the outcome in the retrospective study presented by Lambrechts et al.

Here we present the first prospective evaluation of candidate SNPs of VEGF/VEGFR pathway as potential predictors of clinical outcome in a large and clinically homogenous cohort of mCRC patients treated with first-line FOLFIRI plus BV. Currently available evidences about the potential predictive and/or prognostic power of investigated SNPs are summarized in Table 1.

### Table 1. Investigated SNPs: current evidences from literature.

| Gene       | rs number | Major/Minor allele | Major findings                                                                 |
|------------|-----------|--------------------|--------------------------------------------------------------------------------|
| VEGFA      | 833061    | C/T               | • Associated with PFS and OS in a retrospective cohort of mCRC patients treated with first-line FOLFIRI+BV |
|            |           |                   | • Not associated with clinical outcome in CAPOX+BV arm of CAIRO-2 trial in mCRC |
| VEGFA      | 699946    | A/G               | • Predictive for PFS in patients treated with or without BV in phase III randomized trials. |
| VEGFA      | 699947    | C/A               | • Predictive for OS in E2100 trial of paclitaxel±BV in metastatic breast cancer. |
| VEGFR1     | 7993418   | A/G               | • Not associated with clinical outcome in CAPOX+BV arm of CAIRO-2 trial or in a retrospective analysis of patients treated with or without BV in phase III randomized trials. |
| VEGFR1     | 9582036   | A/C               | • Predictive for PFS in AVOREN trial of IFN-α ± BV in metastatic renal cancer |
| VEGFR1     |           |                   | • Predictive for PFS in AVIOTA trial of gemcitabine+erlotinib±BV in metastatic pancreatic adenocarcinoma |
| VEGFR2     | 11133360  | T/C               | • Associated with PFS in patients treated with BV in phase III randomized trials |
| VEGFR2     | 12505758  | T/C               | • Associated with OS in patients treated with BV in phase III randomized trials |
| VEGFR2     | 2305948   | C/T               | • Associated with response in a retrospective cohort of mCRC patients treated with oxaliplatin-containing chemotherapy+BV |
| EPAS1      | 4145836   | G/A               | • Associated with PFS in patients treated with, but also without BV, in phase III randomized trials |

doi:10.1371/journal.pone.0066774.t001

Patients and Methods

Eligibility Criteria and Study Procedures

Patients with histologically confirmed diagnosis of metastatic colorectal adenocarcinoma were enrolled in the trial if they were more than 18 years old, had at least one measurable lesion according to RECIST 1.0 and had never been treated for metastatic disease. Previous adjuvant oxaliplatin was allowed if more than 12 months had elapsed between the end of adjuvant therapy and relapse. Adequate bone marrow, liver and renal function were required. All involved subjects signed their written informed consent to study treatment and related procedures. The trial was approved by the local ethics committee (Comité Etico Sperimentazione Farmaco - Azienda Ospedaliero-Universitaria Pisa) and clinical investigation was conducted according to the Declaration of Helsinki.

Study treatment consisted of biweekly administrations of BV 5 mg/kg ev at day 1, followed by Irinotecan 165 mg/sqm ev, infused concomitantly with L-Leucovorin 200 mg/sqm ev, followed by 5-fluorouracil 400 mg/sqm ev and 5-fluorouracil 2400 mg/sqm as a 48-h continuous infusion starting on day 1. Irinotecan was administered for a maximum of 12 cycles or until progressive disease, unacceptable toxicities or patients’ refusal. 5-fluorouracil, L-Leucovorin and BV were continued until the disease of progressive disease, unacceptable toxicities or patients’ refusal.

Table 2. Baseline characteristics and RECIST response.

| Tumor Response | N  | CR | PR | SD | PD | \(p^*\) value |
|----------------|----|----|----|----|----|----------------|
| Age, years     |    |    |    |    |    | 0.95           |
| \(\leq65\)     | 274| 16 (6%) | 145 (54%) | 77 (29%) | 31 (12%) |
| >65            | 150| 9 (6%)  | 74 (50%)  | 54 (36%)  | 11 (7%)  |
| Sex            |    |    |    |    |    | 0.040          |
| M              | 252| 12 (5%) | 126 (51%) | 81 (33%) | 30 (12%) |
| F              | 172| 13 (8%) | 93 (55%)  | 50 (30%)  | 12 (7%)  |
| ECOGPS         |    |    |    |    |    | 0.003          |
| 0              | 357| 21 (6%) | 194 (55%) | 111 (31%) | 27 (8%)  |
| 1–2            | 67 | 4 (6%)  | 25 (39%)  | 20 (31%)  | 15 (23%) |
| Primary tumor site |    |    |    |    |    | 0.11           |
| Right colon    | 107| 7 (7%)  | 49 (48%)  | 32 (31%)  | 15 (15%) |
| Left colon     | 180| 13 (7%) | 100 (56%) | 55 (31%)  | 10 (6%)  |
| Rectum         | 122| 5 (4%)  | 67 (55%)  | 38 (31%)  | 12 (10%) |
| Colon, rectum  | 1  |        |        |        |        |                |
| Unknown        | 14 |        |        |        |        |                |
| Mucinous histology |    |    |    |    |    | 0.001          |
| Yes            | 52 | 1 (2%)  | 18 (36%)  | 25 (50%)  | 6 (12%)  |
| No             | 261| 23 (9%) | 149 (57%) | 66 (25%)  | 23 (9%)  |
| NA             | 111| 1 (1%)  | 52 (49%)  | 40 (38%)  | 13 (12%) |
| Liver-only disease |    |    |    |    |    | 0.032          |
| Yes            | 136| 11 (8%) | 77 (57%)  | 37 (27%)  | 10 (7%)  |
| No             | 288| 14 (5%) | 142 (50%) | 94 (33%)  | 32 (11%) |
| Mast site, n   |    |    |    |    |    | 0.016          |
| 1              | 194| 19 (10%) | 100 (52%) | 58 (30%)  | 15 (8%)  |
| >1             | 230| 6 (3%)  | 119 (53%) | 73 (32%)  | 27 (12%) |
| Time to mets   |    |    |    |    |    | 0.34           |
| Synchronous    | 311| 17 (6%) | 169 (56%) | 87 (29%)  | 31 (10%) |
| Metachronous   | 113| 8 (7%)  | 50 (44%)  | 44 (39%)  | 11 (10%) |
| Kohnle Score   |    |    |    |    |    | 0.012          |
| Low            | 194| 19 (10%) | 101 (53%) | 58 (30%)  | 14 (7%)  |
| Intermediate   | 180| 6 (3%)  | 97 (55%)  | 53 (30%)  | 20 (11%) |
| High           | 35 | 0 (0%)  | 14 (41%)  | 15 (44%)  | 5 (15%)  |
| NA             | 15 | 0 (0%)  | 7 (47%)   | 5 (33%)   | 3 (20%)  |
| Primary tumor resected |    |    |    |    |    | 0.86           |
| Yes            | 320| 21 (7%) | 159 (50%) | 107 (34%) | 29 (9%)  |
| No             | 103| 4 (4%)  | 60 (60%)  | 24 (24%)  | 12 (12%) |
| Unknown        | 1  |        |        |        |        |                |
| High LDH       |    |    |    |    |    | 0.077          |
| Yes            | 188| 10 (5%) | 104 (56%) | 52 (28%)  | 19 (10%) |
| No             | 188| 15 (8%) | 93 (51%)  | 60 (33%)  | 16 (9%)  |
| NA             | 48 | 0 (0%)  | 22 (46%)  | 19 (40%)  | 7 (15%)  |
| Prior adjuvant CT |    |    |    |    |    |                |
| No             | 333| 19 (6%) | 183 (56%) | 93 (28%)  | 32 (10%) |
| Yes            | 91 | 6 (7%)  | 36 (40%)  | 38 (42%)  | 10 (11%) |

*P value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.

**Results**

Predictors of Benefit from Bevacizumab

Response was assessed by means of CT scan, that was repeated every 8 weeks. RECIST criteria v1.0 were applied.

Six ml blood samples were collected in EDTA tubes and stored at −20°C.

Statistical Design

Based on our previous retrospective findings, we designed a prospective phase II trial. According to Schoenfeld design, in order to detect a negative effect of VEGFA rs833061 T/T variant compared to C- variants equal to a HR for PFS of 1.7, adopting two-sided \(\alpha = 0.05\) and \(\beta = 0.20\) respectively, and assuming a prevalence of T/T variant of 25%, we estimated to require 199 events.

The association of polymorphisms with PFS and OS was analyzed using Kaplan–Meier curves and the log-rank test.

PFS was defined as the time from the first administration of study treatment until the first documentation of objective disease progression according to RECIST 1.0, or death due to any cause, whichever occurs first. Patients undergoing secondary radical resection of metastatic lesions were censored at the time of surgery.

OS was defined as the time from the first administration of study treatment until the date of death due to any cause.

The associations between polymorphisms and RR were examined using contingency tables and the Cochran-Mantel-Haenszel test.

Since 9 SNPs were tested, the Benjamin and Hochberg method was used to control the false discovery rate (FDR) of multiple hypothesis testing. Polymorphisms that were significantly associated with clinical outcome with an FDR-adjusted \(p\) value of <0.15 were chosen to include in the multivariate model.

In the multivariate Cox regression analysis for PFS and OS, models were adjusted for mucinous histology, ECOG PS, baseline LDH level, number of metastatic sites and primary tumour site. We used the stepwise Cox regression model to choose covariates that were accounted for in the multivariate model. Covariates that remained significant at a 0.1 level in the multivariate analysis were retained.

When applying multiple testing correction for the number of analyzed SNPs, the association of VEGFR2 12505758 C/T variants with clinical outcome was not significant (\(p = 0.14\)).

All analyses were carried out using the SAS statistical package version 9.2.

This study has been completed and is registered in ClinicalTrials.gov, with number NCT01363739. Study treatment was not issued for the purpose of this trial; patients would have received the same regimen independently of their enrollment.

**Genotyping**

Genomic DNA was extracted from peripheral blood using the QIAamp Kit (Qiagen). VEGFA rs833061 C/T, rs699946 A/G and rs699947 A/C, VEGFR1 rs958236 A/C and rs7993418 A/G, VEGFR2 rs11133360 C/T, rs12505758 C/T and rs2305948 C/T and EPAS1 rs4145836 A/G SNPs were genotyped by means of PCR and sequencing. Investigators conducting genetic analyses were blinded to patients' characteristics and clinical outcome.

**Results**

From April 2006 to May 2011, 424 mCRC patients have been enrolled in 35 Italian Oncology Units. Main patients' characteristics and correlations with clinical outcome are summarized in Table 2 and 3.

At a median follow up of 24 months, 292 patients were progressed and 164 died. In the overall population median PFS
Table 3. Baseline characteristics and survival outcomes.

| Predictor                      | Median PFS, mos (95%CI) | HR (95%CI) | P value | Median OS, mos (95%CI) | HR (95%CI) | P value |
|-------------------------------|-------------------------|------------|---------|------------------------|------------|---------|
| **Age, years**                |                         |            |         |                        |            |         |
| ≤65                           | 10.2 (9.5, 10.8)         | 1 (Reference) | 0.22    | 29.6 (23.9, 37.8)      | 1 (Reference) | 0.78    |
| >65                           | 11.8 (10.0, 13.5)        | 0.86 (0.68, 1.09) | 0.49    | 31.2 (23.8, 42.0)      | 0.96 (0.70, 1.31) | 0.69    |
| **Sex**                       |                         |            |         |                        |            |         |
| M                             | 10.3 (9.5, 11.4)         | 1 (Reference) | 0.49    | 26.3 (22.9, 37.8)      | 1 (Reference) | 0.69    |
| F                             | 10.8 (9.6, 11.7)         | 0.92 (0.73, 1.16) | 0.49    | 31.2 (27.3, 44.1)      | 0.94 (0.69, 1.28) | 0.28    |
| ECOGPS                        |                         |            |         |                        |            |         |
| 0                             | 10.9 (10.2, 11.8)        | 1 (Reference) | <.001   | 33.1 (29.8, 42.0)      | 1 (Reference) | <.001   |
| 1–2                           | 7.9 (6.3, 10.0)          | 1.71 (1.27, 2.28) | 0.002   | 18.6 (13.9, 21.4)      | 2.74 (1.90, 3.95) | <.001   |
| **Primary tumor site**        |                         |            |         |                        |            |         |
| Right colon                   | 9.7 (8.8, 10.3)          | 1 (Reference) | 0.002   | 23.5 (19.1, 27.3)      | 1 (Reference) | 0.16    |
| Left colon                    | 11.5 (10.5, 14.0)        | 0.61 (0.46, 0.81) | 0.028   | 42.0 (28.6, 53.5)      | 0.48 (0.33, 0.69) | 0.16    |
| Rectum                        | 10.6 (8.7, 11.8)         | 0.80 (0.60, 1.09) | 0.002   | 32.6 (25.4, 48.5)      | 0.56 (0.38, 0.82) | 0.16    |
| Colon, rectum                 |                         |            |         |                        |            |         |
| Unknown                       |                         |            |         |                        |            |         |
| **Mucinous histology**        |                         |            |         |                        |            |         |
| Yes                           | 9.6 (8.4, 11.2)          | 1 (Reference) | <.001   | 25.4 (19.9, 42.0)      | 1 (Reference) | <.001   |
| No                            | 11.3 (10.4, 12.4)        | 0.76 (0.54, 1.06) | 0.028   | 32.6 (28.6, 38.0)      | 0.69 (0.45, 1.06) | 0.028   |
| NA                            | 8.3 (7.8, 9.5)           | 1.36 (0.89, 2.06) | 0.022   | 24.8 (20.0, 40.3)      | 0.89 (0.50, 1.59) | 0.022   |
| **Liver-only disease**        |                         |            |         |                        |            |         |
| Yes                           | 11.5 (9.8, 12.6)         | 1 (Reference) | 0.028   | 33.0 (23.7, 53.5)      | 1 (Reference) | 0.14    |
| No                            | 10.2 (9.6, 11.1)         | 1.34 (1.03, 1.75) | 0.028   | 29.2 (23.8, 37.8)      | 1.29 (0.91, 1.81) | 0.028   |
| **Mst site, n**               |                         |            |         |                        |            |         |
| 1                             | 11.9 (10.5, 13.7)        | 1 (Reference) | <.001   | 34.6 (29.6, 53.5)      | 1 (Reference) | <.001   |
| >1                            | 9.8 (9.3, 10.5)          | 1.61 (1.27, 2.05) | 0.094   | 24.8 (21.6, 31.2)      | 1.79 (1.30, 2.48) | 0.066   |
| **Time to mets**              |                         |            |         |                        |            |         |
| Synchronous                   | 10.3 (9.6, 11.3)         | 1 (Reference) | 0.94    | 26.3 (23.5, 32.1)      | 1 (Reference) | 0.066   |
| Metachronous                  | 10.5 (9.5, 13.5)         | 0.99 (0.76, 1.28) | 0.94    | 38.0 (29.6, 49.2)      | 0.72 (0.50, 1.03) | 0.94    |
| **Kohne Score**               |                         |            |         |                        |            |         |
| Low                           | 11.9 (10.5, 13.5)        | 1 (Reference) | <.001   | 34.6 (29.8, 53.5)      | 1 (Reference) | <.001   |
| Intermediate                  | 10.2 (9.6, 11.3)         | 1.50 (1.16, 1.93) | 0.022   | 29.1 (23.2, 37.8)      | 1.59 (1.12, 2.25) | 0.022   |
| High                          | 7.9 (6.6, 8.6)           | 2.47 (1.64, 3.72) | 0.016   | 18.9 (10.2, 21.4)      | 3.67 (2.26, 5.96) | 0.016   |
| NA                            | 9.8 (7.3, 12.2)          | 1.73 (1.00, 2.98) | 0.016   | 31.2 (6.9, 39.3)       | 1.79 (0.88, 3.64) | 0.016   |
| **Primary tumor resected**    |                         |            |         |                        |            |         |
| Yes                           | 10.8 (10.1, 11.6)        | 1 (Reference) | 0.022   | 31.6 (27.3, 44.1)      | 1 (Reference) | 0.008   |
| No                            | 9.5 (8.2, 11.0)          | 1.37 (1.04, 1.81) | 0.35    | 23.5 (19.1, 32.6)      | 1.62 (1.12, 2.33) | 0.35    |
| Unknown                       |                         |            |         |                        |            |         |
| **High LDH**                  |                         |            |         |                        |            |         |
| Yes                           | 10.2 (9.3, 11.3)         | 1 (Reference) | 0.016   | 28.6 (21.8, 42.0)      | 1 (Reference) | 0.35    |
| No                            | 11.1 (10.1, 13.1)        | 0.77 (0.60, 0.98) | 0.83    | 31.6 (24.8, 38.4)      | 0.83 (0.60, 1.16) | 0.83    |
| NA                            | 9.5 (8.1, 11.0)          | 1.23 (0.85, 1.79) | 0.90    | 31.2 (19.6, 49.2)      | 1.14 (0.69, 1.87) | 0.90    |
| **Prior adjuvant CT**         |                         |            |         |                        |            |         |
| Yes                           | 10.4 (9.6, 11.4)         | 1 (Reference) | 0.28    | 28.8 (23.8, 33.0)      | 1 (Reference) | 0.28    |
| No                            | 10.5 (9.6, 13.7)         | 1.02 (0.77, 1.34) | 0.82    | 38.0 (25.9, 53.5)      | 0.82 (0.56, 1.19) | 0.82    |

*P value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.
doi:10.1371/journal.pone.0066774.t003

Predictors of Benefit from Bevacizumab

PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e66774
Secondary Endpoints

As reported in Table 6 and 7, no significant association of VEGFR rs699946 A/G and rs699947 A/C, VEGFR1 rs9582036 A/C and rs7993418 A/G, VEGFR2 rs11133360 C/T and rs2305948 C/T variants with clinical outcome was observed. A significant association of VEGFR2 12505758 C/T variants with clinical outcome was found in terms of PFS (p = 0.045), but not RR (p = 0.50) or OS (p = 0.12) using co-dominant genetic model. Patients with at least one C- allele (N = 118) showed a median PFS of 9.5 months compared to 10.9 months of patients homozygous for T/T (N = 306) (HR: 1.34 [95%CI: 1.06–1.75], p = 0.015, dominant genetic model) (Figure 3). Patients with at least one C- allele showed a median OS of 23.5 months compared to 32.1 months of patients homozygous for T/T (N = 306) (HR: 1.36 [95%CI: 1.06–1.75], p = 0.015, dominant genetic model) (Table S1).

Primary Endpoint

VEGFA rs833061 C/T SNP was successfully genotyped in 423 cases. No association of VEGFA rs833061 C/T variants with clinical outcome was observed (Table 4 and 5). Patients homozygous for T/T (N = 147) showed a median PFS of 10.2 months vs 10.0 months for patients bearing at least one C- allele (N = 276) (HR: 1.17 [95%CI: 0.91–1.50], p = 0.218) (Figure 1). Also in terms of OS, patients homozygous for T/T showed a median OS of 32.1 months vs 29.9 months for patients bearing at least one C- allele (HR: 0.96 [95%CI: 0.70–1.33], p = 0.733) (Figure 2).

Discussion

In recent years, the search for biomarkers able to predict benefit from BV has been one of the most competitive translational research areas. Despite many efforts and some promising candidates, no markers have provided reliable and reproducible results, thus making this unsolved challenge extremely intriguing. The question remains why has it been so difficult to identify clinical relevant predictive markers for BV.

One of the most compelling reasons is the biologic complexity of tumor angiogenesis which is recognized as one of the hallmarks of cancer. In recent years data suggest the role of multiple pathways in the growth of new tumor vessels, leading to investigate the simultaneous inhibition of multiple angiogenic targets as a potentially efficacious strategy [16]. The role of several cell types in the development of such an intricate network of signals has also emerged and the contribution of both stromal cells and bone-marrow derived vascular progenitors, recruited and stimulated by hypoxic conditions, has been evidenced [17]. The relevance of tumor microenvironment as a crucial actor in new vessels’ growth and stabilization and the critical implication of the extracellular matrix in supporting neoangiogenesis are now well-established, thus confirming the contribution of both host- and tumor-related factors to the so called “angiogenic balance”.

All the mechanisms of action of anti-VEGFA therapy remain unclear since blockade of circulating VEGF may impact not only tumors, but also stroma and endothelial cells’ proliferation and maturation. While BV antiangiogenic properties were firstly attributed to the inhibition of endothelial cells’ proliferation, today several different biologic effects are recognized, such as the inhibition of bone marrow-derived progenitors, the normalization of vessels’ structure, the vascular “constriction”, and the disruption of cancer stem cells’ niche, the direct effect on tumor cells and the interaction with the host immune system. As a consequence of these multiple mechanisms of action, the translation of in vitro and in vivo findings into the human model is not immediate and several difficulties make the development of efficacious preclinical models extremely complicated.

Another complicating factor in the identification of biomarkers of BV is that as a single agent has very limited antitumor effect, so that the confounding effect of chemo-backbone overshadows the BV effect. Moreover, non responding patients according to RECIST also achieve benefit in terms of prolonged time to tumor progression [18].

Figure 1. VEGFA 833061 C/T allelic variants and PFS. doi:10.1371/journal.pone.0066774.g001

Figure 2. VEGFA 833061 C/T allelic variants and OS. doi:10.1371/journal.pone.0066774.g002
Despite these challenges, some potential candidates have emerged from different retrospective clinical trials. Although these markers were often considered worthy of further investigation, none of them was validated and entered clinical practice. Our group recently showed the promising association of VEGFA rs833061C/T allelic variants with clinical outcome. However, our biomarker was identified retrospectively in a clinical cohort, which was not randomized, and is biased by the multiple-testing approach [10].

This clinical trial represents our attempt to take up the challenge of validation, claimed by statisticians and methodology experts since the introduction of targeted drugs into clinical practice [19]. The need to validate retrospective findings, by conducting prospective trials is nowadays a matter of fact. Although randomized studies with an interaction design or a so-called “marker-based strategy” would provide the highest level of evidence, they would also require extremely large numbers of events [20]. A more pragmatic, but methodologically correct proposal is the “retrospective-prospective” approach, in which the hypothesis generated by the retrospective experience is prospectively challenged in a new cohort [21]. Up today, in spite of the high number of potentially interesting markers emerging from retrospective series, prospective trials with a formal statistical hypothesis have never been conducted. To the best of our knowledge, our work represents the first proof of concept sustaining this approach in the field of colorectal oncology.

The trial, designed on the basis of our retrospective findings, attests the failure of VEGFA rs833061C/T SNP as a potential predictor of benefit from BV and does not confirm previous results about other candidate SNPs.

With regard to VEGFR2 12505758 C/T SNP, whose prognostic rather than predictive impact has been previously suggested [16], we should acknowledge that the significance of the correlation

---

### Table 4. VEGFA 833061 SNP allelic variants and survival.

|            | Progression-Free Survival | Overall Survival |
|------------|---------------------------|------------------|
|            | N            | Median PFS, mos (95%CI) | HR (95%CI) | P* value | Median OS, mos (95%CI) | HR (95%CI) | P* value |
| VEGFA 833061 |              |                        |            |       |                        |            |       |
| TT         | 147          | 10.2 (9.1, 11.1)        | 1 (Reference) | 32.1 (23.8, 53.5) | 1 (Reference) |
| CT         | 197          | 10.6 (9.6, 11.9)        | 0.85 (0.66, 1.09) | 0.38 | 30.9 (23.7, 38.4) | 1.05 (0.74, 1.49) | 0.95 |
| CC         | 79           | 10.4 (9.4, 12.7)        | 0.85 (0.61, 1.17) | 29.8 (21.6, 44.1) | 1.00 (0.64, 1.55) |

*P value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.

doi:10.1371/journal.pone.0066774.t004

### Table 5. VEGFA 833061 SNP allelic variants and response.

|            | Tumor Response |
|------------|----------------|
|            | N  | CR | PR | SD | PD | p* value |
| VEGFA 833061 |    |    |    |    |    |          |
| TT         | 147 | 4 (3%) | 83 (57%) | 48 (33%) | 11 (8%) |          |
| CT         | 197 | 14 (7%) | 96 (50%) | 61 (32%) | 21 (11%) | 0.99     |
| CC         | 79  | 7 (9%) | 39 (50%) | 22 (28%) | 10 (13%) |          |

*p value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.

doi:10.1371/journal.pone.0066774.t005

---

### Table 6. Other candidate VEGFA, VEGFR1, VEGFR2 and EPAS1 SNPs allelic variants and RECIST response.

|            | Tumor Response |
|------------|----------------|
|            | N  | CR | PR | SD | PD | p* value |
| VEGFA 699946 |    |    |    |    |    |          |
| AA         | 257 | 17 (7%) | 127 (50%) | 80 (32%) | 29 (11%) |          |
| AG         | 144 | 8 (6%) | 77 (55%) | 47 (33%) | 9 (6%) | 0.59     |
| GG         | 23  | 0 (0%) | 15 (65%) | 4 (17%) | 4 (17%) |          |
| VEGFA 699947 |    |    |    |    |    |          |
| CC         | 148 | 4 (3%) | 84 (57%) | 49 (33%) | 10 (7%) |          |
| AC         | 199 | 14 (7%) | 97 (50%) | 61 (31%) | 22 (11%) | 0.94     |
| AA         | 77  | 7 (9%) | 38 (50%) | 21 (28%) | 10 (13%) |          |
| VEGFR1 7993418 |    |    |    |    |    |          |
| AA         | 270 | 12 (5%) | 142 (54%) | 87 (32%) | 24 (9%) |          |
| AG         | 138 | 12 (9%) | 68 (50%) | 39 (29%) | 17 (13%) | 0.89     |
| GG         | 16  | 1 (6%) | 9 (56%) | 5 (31%) | 1 (6%) |          |
| VEGFR1 9582036 |    |    |    |    |    |          |
| AA         | 241 | 11 (5%) | 128 (54%) | 75 (32%) | 23 (10%) |          |
| AC         | 158 | 11 (7%) | 80 (51%) | 47 (30%) | 18 (12%) | 0.72     |
| CC         | 25  | 3 (13%) | 11 (46%) | 9 (38%) | 1 (4%) |          |
| VEGFR2 11133360 |    |    |    |    |    |          |
| TT         | 143 | 9 (6%) | 81 (57%) | 38 (27%) | 13 (9%) |          |
| CT         | 212 | 13 (6%) | 103 (50%) | 69 (33%) | 23 (11%) | 0.45     |
| CC         | 69  | 3 (4%) | 35 (51%) | 24 (35%) | 6 (9%) |          |
| VEGFR2 12505758 |    |    |    |    |    |          |
| TT         | 306 | 22 (7%) | 156 (52%) | 95 (31%) | 29 (10%) |          |
| CT         | 107 | 3 (3%) | 55 (53%) | 34 (33%) | 12 (12%) | 0.50     |
| CC         | 11  | 0 (0%) | 8 (73%) | 2 (18%) | 1 (9%) |          |
| VEGFR2 2305948 |    |    |    |    |    |          |
| CC         | 354 | 22 (6%) | 186 (54%) | 106 (31%) | 33 (10%) |          |
| CT†        | 66  | 3 (4%) | 33 (47%) | 25 (36%) | 9 (13%) | 0.16     |
| TT†        | 4   |      |      |      |      |          |
| EPAS1 4145836 |    |    |    |    |    |          |
| GG         | 332 | 22 (7%) | 175 (54%) | 96 (29%) | 33 (10%) |          |
| AG†        | 87  | 3 (3%) | 44 (48%) | 35 (38%) | 9 (10%) | 0.18     |
| AA†        | 5   |      |      |      |      |          |

*p value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.

doi:10.1371/journal.pone.0066774.t006
with PFS was lost when applying the multiple testing correction. However, since VEGFR2 is acquiring growing relevance as a consequence of the affirmation of other targeted agents interfering with its function, like aflibercept and regorafenib, these results may deserve further investigation.

The encouraging result reported in terms of OS (median OS: 29.9 months) probably mirrors the accessibility of these patients, enrolled between April 2006 and May 2011, to all cytotoxics and targeted agents indicated for the treatment of mCRC as well as the improvement of locoregional techniques and the increasing expertise of committed surgeons.

In conclusion, though recognizing the relevance of preliminary retrospective experiences as essential starting points to generate new work-hypotheses, the present study confirms the absolute importance of the prospective validation as an essential step on biomarkers’ way toward clinical application.

Moreover, based on the complexity of tumor angiogenesis biology and the involvement of multiple actors in this process, it seems rather unlike that a single germ-line SNP might account for the efficacy of BV by itself. The failure of the “candidate SNP strategy” opens the way to new questions about the possibility to actually exploit the pharmacogenetic approach to identify predictors of benefit from BV. We believe that future directions in this field of research should necessarily include more comprehensive approaches, to provide an extensive overview of the whole genome. A genome wide association (GWAS) study is currently ongoing, to assess the correlation of genetic profiles with clinical outcome in a wide population of mCRC patients receiving upfront chemotherapy plus BV. A wide biostatistical program is

Table 7. Other candidate VEGFA, VEGFR1, VEGFR2 and EPAS1 SNPs allelic variants and survival outcomes.

|                  | Progression-Free Survival | Overall Survival |
|------------------|---------------------------|------------------|
|                  | N | Median PFS, mos (95%CI) | HR (95%CI) | P* value | Median OS, mos (95%CI) | HR (95%CI) | P* value |
| **VEGFA 699946** |   |                         |           |          |                        |           |          |
| AA               | 257 | 10.4 (9.8, 11.5) | 1 (Reference) |         | 29.1 (23.5, 37.8) | 1 (Reference) |         |
| AG               | 144 | 10.5 (9.6, 11.9) | 1.03 (0.80, 1.32) | 0.34 | 33.0 (23.9, 42.0) | 0.97 (0.70, 1.35) | 0.69 |
| GG               | 23  | 9.6 (8.1, 11.0) | 1.44 (0.87, 2.39) |         | 32.1 (16.3, 49.2) | 1.30 (0.68, 2.50) |         |
| **VEGFA 699947** |   |                         |           |          |                        |           |          |
| CC               | 148 | 10.2 (9.5, 11.1) | 1 (Reference) |         | 32.6 (24.8, 53.5) | 1 (Reference) |         |
| AC               | 199 | 10.7 (9.6, 11.8) | 0.86 (0.66, 1.11) | 0.46 | 30.9 (23.5, 38.4) | 1.11 (0.78, 1.57) |         |
| AA               | 77  | 10.3 (9.4, 12.7) | 0.86 (0.62, 1.19) |         | 29.2 (21.2, 37.8) | 1.06 (0.68, 1.65) | 0.84 |
| **VEGFR1 7993418** |   |                         |           |          |                        |           |          |
| AA               | 270 | 10.5 (9.6, 11.6) | 1 (Reference) |         | 31.6 (25.9, 38.0) | 1 (Reference) |         |
| AG               | 138 | 10.3 (9.6, 11.3) | 1.15 (0.90, 1.47) | 0.52 | 28.6 (21.7, 37.8) | 1.15 (0.83, 1.58) | 0.57 |
| GG               | 16  | 9.2 (7.8, 16.6) | 0.97 (0.51, 1.84) |         | 60.4 (20.0, 60.4) | 0.82 (0.35, 1.90) |         |
| **VEGFR1 9582036** |   |                         |           |          |                        |           |          |
| AA               | 241 | 11.0 (10.0, 12.5) | 1 (Reference) |         | 32.6 (26.3, 44.1) | 1 (Reference) |         |
| AC               | 158 | 10.1 (9.5, 10.8) | 1.25 (0.98, 1.58) | 0.19 | 28.6 (23.3, 34.6) | 1.17 (0.85, 1.60) |         |
| CC               | 25  | 10.5 (7.8, 14.0) | 1.15 (0.68, 1.96) |         | 37.8 (20.0, 60.4) | 0.99 (0.51, 1.92) | 0.62 |
| **VEGFR2 11133360** |   |                         |           |          |                        |           |          |
| TT               | 143 | 10.5 (9.7, 11.5) | 1 (Reference) |         | 33.0 (23.5, 60.4) | 1 (Reference) |         |
| CT               | 212 | 10.8 (9.5, 12.3) | 0.92 (0.71, 1.20) | 0.60 | 30.9 (25.4, 34.6) | 1.17 (0.83, 1.66) | 0.42 |
| CC               | 69  | 10.0 (8.6, 11.9) | 1.08 (0.77, 1.51) |         | 28.6 (20.8, 48.5) | 1.35 (0.85, 2.14) |         |
| **VEGFR2 12505758** |   |                         |           |          |                        |           |          |
| TT               | 306 | 10.9 (10.1, 11.7) | 1 (Reference) |         | 32.1 (26.3, 38.4) | 1 (Reference) |         |
| CT               | 107 | 9.5 (8.8, 11.1) | 1.34 (1.03, 1.74) | 0.045 | 23.5 (19.8, 29.9) | 1.41 (1.00, 1.99) | 0.12 |
| CC               | 11  | 10.7 (9.3, 11.2) | 1.57 (0.82, 2.98) |         | 42.9 (21.7, 62.9) | 0.75 (0.24, 2.38) |         |
| **VEGFR2 2305948** |   |                         |           |          |                        |           |          |
| CC               | 354 | 10.4 (9.6, 11.1) | 1 (Reference) |         | 29.9 (25.4, 34.6) | 1 (Reference) |         |
| CT†             | 66  | 11.5 (9.8, 12.5) | 0.91 (0.66, 1.26) | 0.57 | 29.8 (21.5, 49.7) | 0.89 (0.58, 1.37) | 0.60 |
| TT†             | 4   |                         |           |          |                        |           |          |
| **EPAS1 4145836** |   |                         |           |          |                        |           |          |
| GG               | 332 | 10.6 (9.9, 11.5) | 1 (Reference) |         | 31.6 (25.9, 37.8) | 1 (Reference) |         |
| AG†             | 87  | 10.1 (8.1, 11.5) | 0.95 (0.71, 1.25) | 0.69 | 23.5 (19.9, 49.7) | 1.15 (0.80, 1.65) | 0.46 |
| AA†             | 5   |                         |           |          |                        |           |          |

*P value was based on Cochran-Mantel-Haenszel test for response and log-rank test for PFS and OS.
†Dominant model.

doi:10.1371/journal.pone.0066774.t007
also planned in order to implement the interpretation of data coming from the high number of investigated SNPs in this exploratory GWAS analysis. In particular, adequate statistical tools, such as the multifactor dimensionality reduction (MDR) and the classification and regression tree (CRT) analyses will be applied to accurately estimate and identify gene-gene interactions as previously described [22–23]. Two independent cohorts of patients randomized to receive or not the antiangiogenic will serve as validation sets to verify the predictive impact of identified profiles. In spite of disappointing results reported in this field, the challenge of identifying predictors of benefit from antiangiogenic drugs still represents a hot topic, with increasing consequences on clinical practice. In fact, two phase III randomized trials, ML18147 [24] and BEBYP [25], have recently demonstrated the efficacy of prosecuting BV beyond disease progression in mCRC patients, thus making this field even more complicated. These achievements open the way to new questions about the meaning of traditional clinical progression and its biologic mechanisms while underlining the need for biomarkers of acquired resistance to BV.

### Supporting Information

#### Table S1 Multivariable Cox regression models for PFS and OS.

(DOCX)

#### Author Contributions

Conceived and designed the experiments: FL CC AF HJL. Performed the experiments: FL TW WZ AR PB LB. Analyzed the data: FL CC DY AF HJL. Contributed reagents/materials/analysis tools: FL CC LS MS CA GA S. Lonardi S. Lucchesi FD FG MR GT. Wrote the paper: FL CC AF HJL.

### References

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335–42.

2. Giantonio BJ, Catalano PJ, Meroxpl NJ, O’Dwyer PJ, Mitchell EP, et al. (2007) Bevacizumab in combination with oxaplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539–44.

3. Van Cutsem E, Tabernero J, Lakomy R, Preven H, Prausova J, et al. (2012) Addition of Alibhercept to Fluorouracil, Leucovorin, and Irinotecin Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaplatin-Based Regimen. J Clin Oncol 30(20): 3499–506.

4. Grothey A, Van Cutsem E, Soherbo A, Siena S, Falcone A, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863): 303–12.

5. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6): 327–30.

6. Bocci G, Loupakis F (2011) Bevacizumab pharmacogenomics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics 12(8): 1077–80.

7. Liu P, Weaver VM, Webb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4): 395–406.

8. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6): 417–27.

9. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672–8.

10. Loupakis F, Ruzzo A, Salvatore L, Ceremolini C, Masi G, et al. (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11: 247.

11. Paule J, Wessels JA, Gelderblom H, van der Straaten T, Punt CJ, et al. (2011) Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 22(5): 1147–53.

12. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, et al. (2011) Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxalipatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17(17): 5783–92.

13. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, et al. (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14(22): 7534–63.

14. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, et al. (2012) VEGF Polymorphisms and Clinical Outcome in Patients Treated With Bevacizumab. Eur J Canc 47(S1): S173.

15. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, et al. (2008) Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer: ECOG 2100. J Clin Oncol 26(28): 4672–8.

16. Loupakis F, Ruzzo A, Salvatore L, Ceremolini C, Masi G, et al. (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11: 247.

17. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, et al. (2008) Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer: ECOG 2100. J Clin Oncol 26(28): 4672–8.

18. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, et al. (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26(2): 185–9.
19. Sargent DJ, Conley BA, Allegra C, Collette L. (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9): 2020–7.
20. Mandrekar SJ, Sargent DJ. (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27(24): 4027–34.
21. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. (2010) Biomarkers and surrogate endpoints—the challenge of statistical validation. Nat Rev Clin Oncol. 7(6): 309–17.
22. Liu L, Wu C, Wang Y, Zhong R, Wang F, et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis. 32(3): 336–42.
23. Zhong R, Liu L, Zou L, Sheng W, Zhu B, et al. (2013) Genetic variations in the TGFβ signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis. 34(4): 936–42.
24. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14(1): 29–37.
25. Masì G, Loupakis F, Salvatore I, Cremoni C, Formaro L, et al. (2012) Randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 23(s9): ix9.